Table 1. Clinical parameters of HCC patients analyzed.
| Clinical parameters | Value | ||
| Total number of patients | 142 | ||
| Gender-male, n (%) | 119 (83.8%) | ||
| Age (years) | 56.2±13.0 | ||
| HBsAg-positive, n (%) | 108 (76.1%) | ||
| Anti-HCV-positive, n (%) | 48 (33.8%) | ||
| Cirrhosis, n (%) | 98 (69.0%) | ||
| Alcoholism, n (%) | 45 (31.7%) | ||
| Microvascular invasion, n (%) | 54 (38.0%) | ||
| Macrovascular invasion, n (%) | 37 (26.1%) | ||
| Capsule, n (%) | 97 (68.3%) | ||
| Ascites, n (%) | 16 (11.3%) | ||
| Histology grading | |||
| I, n (%) | 4 (2.8%) | ||
| II, n (%) | 31 (21.8%) | ||
| III, n (%) | 88 (62.0%) | ||
| IV, n (%) | 19 (13.4%) | ||
| Tumor size (diameter, cm) | 5.7±13.0 | ||
| Alpha-fetoprotein (ng/mL) | 5426.7±38892.2 | ||
| Albumin (g/dL) | 4.0±0.6 | ||
| Bilirubin (mg/dL) | 1.3±1.7 | ||
| Prothrombin time (seconds) | 12.3±1.6 | ||
| Creatinine (mg/dL) | 1.2±0.9 | ||
| AST (U/L) | 69.7±98.9 | ||
| ALT (U/L) | 88.0±147.6 | ||
| ephrinA5-L (mRNA level) | T | 0.83±0.08 | |
| N | 1.10±0.26 | ||
| ephrinA5-S (mRNA level) | T | 0.78±0.07 | |
| N | 1.71±0.42 | ||